Andrew A. F. Hack's Net Worth
$425 Million
Who is Andrew A. F. Hack?
Andrew A. F. Hack has an estimated net worth of $425 Million. This is based on reported shares across multiple companies, which include DYNAVAX TECHNOLOGIES CORP, Atea Pharmaceuticals, Inc., Editas Medicine, Inc., Nuvalent, Inc., BCLS Acquisition Corp., Mersana Therapeutics, Inc., and Allena Pharmaceuticals, Inc..
SEC CIK
Andrew A. F. Hack's CIK is 0001657434
Past Insider Trading and Trends
2018 was Andrew A. F. Hack's most active year for acquiring shares with 20 total transactions. Andrew A. F. Hack's most active month to acquire stocks was the month of April. 2018 was Andrew A. F. Hack's most active year for disposing of shares, totalling 31 transactions. Andrew A. F. Hack's most active month to dispose stocks was the month of January. 2020 saw Andrew A. F. Hack paying a total of $36,524,462.58 for 10,670,777 shares, this is the most they've acquired in one year. In 2022 Andrew A. F. Hack cashed out on 4,500,000 shares for a total of $61,440,000.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
DYNAVAX TECHNOLOGIES CORP (DVAX) Snapshot price: $12.905
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -62.11% | -1.50M |
$14.39 | -$21,585,000.00 | 915K |
Aug 8
| |||
Form 4
| -17.15% | -500.00K |
$12.68 | -$6,340,000.00 | 2.42M |
Jun 14
| |||
Form 4
| +100.00% | 5.36K |
—
|
—
| 10.71K |
May 26
| |||
Form 4
| -25.54% | -1.00M |
$10.55 | -$10,550,000.00 | 2.92M |
May 18
| |||
Form 4
| -27.70% | -1.50M |
$11.60 | -$17,400,000.00 | 3.92M |
Dec 6
| |||
Form 4
| -35.65% | -3.00M |
$14.68 | -$44,040,000.00 | 5.42M |
Aug 15
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 26
| |||
Form 4
| -1.28% | -109.00K |
$16.22 | -$32,440,000.00 | 8.41M |
Aug 27
| |||
Form 4
| -0.01% | -1.00K |
$10.80 | -$24,300,000.00 | 8.52M |
Aug 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 28
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 28
| |||
Form 4
| +13.29% | 1M |
$5.00 | $5,000,000.00 | 8.53M |
May 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 11
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 12
| |||
| No matching records found | |||||||||
Atea Pharmaceuticals, Inc. (AVIR) Snapshot price: $4.15
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 5.62M |
$24.00 |
—
| 5.62M |
Nov 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 29
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Editas Medicine, Inc. (EDIT) Snapshot price: $7.15
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
$13.94 | -$102,804.45 |
0
|
Scheduled
|
Feb 4
| ||
Form 4
|
—
|
0
|
$14.48 | -$112,000.00 |
0
|
Scheduled
|
Jan 4
| ||
Form 4/A
|
∞
| 5.28K |
$3.23 | $17,067.32 | 5.28K |
Scheduled
|
Nov 23
| ||
Form 4/A
|
∞
| 6K |
$3.23 | $19,380.00 | 6K |
Scheduled
|
Oct 26
| ||
Form 4
|
—
|
0
|
$17.31 | -$114,498.44 |
0
|
Scheduled
|
Nov 23
| ||
Form 4
|
—
|
0
|
$16.09 | -$115,320.00 |
0
|
Scheduled
|
Oct 26
| ||
Form 4
|
—
|
0
|
$19.28 | -$204,800.00 |
0
|
Scheduled
|
Sep 28
| ||
Form 4
|
—
|
0
|
$19.35 | -$257,500.00 |
0
|
Scheduled
|
Aug 31
| ||
Form 4
|
—
|
0
|
$25.28 | -$267,110.00 |
0
|
Scheduled
|
Jun 1 - Jun 4
| ||
Form 4
|
—
|
0
|
$27.26 | -$864,600.00 |
0
|
Scheduled
|
Mar 16 - Mar 20
| ||
Form 4
|
—
|
0
|
$20.35 | -$499,200.00 |
0
|
Scheduled
|
Feb 14 - Feb 16
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 7
| |||
Form 4
|
—
|
0
|
$13.96 | -$314,149.18 |
0
|
Scheduled
|
Dec 15 - Dec 19
| ||
Form 4
|
—
|
0
|
$14.16 | -$218,505.00 |
0
|
Scheduled
|
Nov 17 - Nov 20
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 1
| |||
Form 4
|
—
|
0
|
$11.22 | -$47,910.00 |
0
|
Scheduled
|
Feb 15
| ||
Form 4
|
—
|
0
|
$11.22 | -$239,550.00 |
0
|
Scheduled
|
Jan 11
| ||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Nuvalent, Inc. (NUVL) Snapshot price: $78.58
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 2.5K |
—
|
—
| 2.5K |
Jun 12
| |||
Form 4
| -24.60% | -880.00K |
$72.77 | -$64,035,958.59 | 2.7M |
Mar 27
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 15
| |||
Form 4
| +4.35% | 149.25K |
$33.50 | $4,999,975.50 | 3.58M |
Nov 3
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 16
| |||
Form 4
|
∞
| 3.43M |
$17.00 |
—
| 3.43M |
Aug 2
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jul 28
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
BCLS Acquisition Corp. No price found
Chief Financial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 487.5K |
$10.00 | $4,875,000.00 | 487.5K |
Oct 26
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||